NIH has renewed and expanded its support for a USC-led consortium developing AI to decode and treat Alzheimer's using imaging and genomic data.
Key Details
- 1NIH total investment in the AI4AD project now totals $30.7 million, with a new $12.6 million award supporting the next phase (AI4AD2).
- 2AI4AD2 unites 10 investigators and 23 co-investigators from 10 institutions.
- 3The project integrates whole-genome sequencing, brain imaging, cognitive tests, and biological data from over 58,000 participants across 57 cohorts.
- 4New 'genomic language models' will analyze genomic sequences for disease-associated DNA changes.
- 5AI tools developed previously demonstrated >90% accuracy detecting Alzheimer's markers from over 80,000 brain scans.
- 6The initiative also focuses on inclusive, multi-ancestry research and genome-guided drug discovery.
Why It Matters
This large-scale effort could redefine Alzheimer's diagnosis and treatment by combining AI-powered brain imaging analysis with genomics, enabling precision medicine approaches. It also addresses diversity and reproducibility issues in neuroimaging and biomarker AI research.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.